大肠癌基因产物表达与其浸润转移关系的研究

目的 为了进一步研究大肠癌的生物学行为。方法 我们用SP方法,对102例大肠癌、癌旁粘膜及转移淋巴结进行癌基因蛋白P_(53),ras和C—erbB—2的癌基因蛋白产物P_(21),P_(185)进行检测,对其表达特征及临床病理学意义做了初步研究。结果 为P_(53)与P_(21)主要在癌细胞中表达,并随着癌组织的分化降低,浸润加深,表达逐渐增强。C—erbB—2也主要在癌细胞中表达,但它的表达与瘤组织的浸润深度无关,而与癌组织的分化程度、淋巴结转移有关。结论 三种癌基因蛋白在癌的移行粘膜中有不同程度的表达,推测该处已有癌基因的激活。     

VEGF、MVD和LN与大肠癌微转移的关系

 目的
探讨血管内皮生长因子(VEGF）、微血管密度(MVD）和层黏连蛋白(Laminin,LN）在大肠正常黏膜组织、大肠腺瘤
组织及大肠癌组织中的表达及临床意义。方法应用免疫组织化学SP法检测18例正常大肠黏膜组织、26例大肠腺瘤组
织和68例大肠癌组织中VEGF和LN的表达水平及MVD计数,并分析他们与大肠癌微转移的关系。结果从大肠正常黏膜
逐步发展为大肠癌的过程中,VEGF的表达水平、MVD计数及基底膜明显缺损率均逐渐增加,LN表达减少,大肠癌组
织中VEGF的阳性表达率和MVD计数与大肠癌的浸润深度、淋巴结转移、Dukes分期有关(P<0.05）。大肠癌组织中基
底膜缺损程度与淋巴结转移、Dukes分期有关(P<0.05）。结论 肿瘤的血管形成和LN的表达与大肠癌的淋巴结转移
、Dukes分期等临床病理特征密切相关,联合检测VEGF、MVD和LN的表达对判断大肠癌的浸润和转移倾向,进而估计
患者的恶性程度。     

EGFR、VEGF表达与大肠癌淋巴结及肝转移的相关性

目的：探讨EGFR、VEGF在大肠癌组织中的表达与淋巴结及肝转移的相关性。方法：应用免疫组化技术检测60例大肠癌（其中淋巴结转移33例，肝转移30例）组织中EGFR、VEGF蛋白的表达，分析其表达水平的差异。结果：EGFR、VEGF表达与TNM分期、淋巴结转移和肝转移有相关性（P〈0．05）。EGFR与VEGF的高表达成正相关。结论：EGFR和VEGF的过度表达在大肠癌的发病过程中具有协同效应。EGFR和VEGF的联合检测对评估大肠癌淋巴结转移及肝转移有重要意义。     

血管内皮生长因子(VEGF)和血清癌胚抗原(CEA)在直肠癌中的表达及其临床意义

目的 探讨血管内皮生长因子(VEGF)和血清癌胚抗原(CEA)在直肠癌中的表达意义.方法 选择60例直肠癌患者为研究对象,并选取同期体检健康者60例作为对照组.使用免疫化学发光法和免疫组化法分别测定血清CEA水平和VEGF蛋白表达水平,分析其表达水平及临床关系.结果 ①研究组血清中CEA检测值明显高于对照组,P＜0.05;②在不同直肠癌TNM分期中,肿瘤组织中CEA阳性率除T1、T2组之间无统计学差异(P =0.153)外,其余各组比较均有统计学差异(P＜0.05);在N分期不同阶段,肿瘤组织CEA阳性率各组间比较差异有统计学意义;在不同M分期中,CEA阳性率分别为43.8％ (M0)、88.7％ (M1),组间比较差异有统计学意义;在不同病理分期中CEA阳性率:Ⅰ期～Ⅱ期与Ⅲ期～Ⅳ期比较差异有统计学意义(P＜0.05),Ⅰ期与Ⅱ期、Ⅲ期与Ⅳ期组间比较差异没有统计学意义(P＞0.05);③肿瘤组织中VEGF表达与肿瘤浸润程度(T分期)有关(P=0.01),与淋巴转移程度(N分期)相关(P-0.03),与临床病理分期有相关性(P=0.009).结论 血管内皮生长因子(VEGF)和血清癌胚抗原(CEA)均与直肠癌的发病密切相关,并与临床TNM分期表现出明显相关性,对直肠癌的临床诊断、治疗和预后有重要意义.     

常见消化道恶性肿瘤患者血清VEGF表达水平及其临床意义

目的研究血管内皮生长因子在常见恶性消化道肿瘤患者血清中的水平及其临床意义.方法应用酶联免疫吸附法(ELISA)检测210例恶性消化道肿瘤患者及87例对照者血清中血管内皮生长因子(vascular endothelial growth factor,VEGF)水平.结果肿瘤患者血清VEGF平均水平为201 ng/L,对照组为76.21 ng/L,两组差别有统计学意义(P＜0.001);有负荷组患者血清VEGF水平高于无负荷组(P＜0.001).血清VEGF水平与肿瘤分化程度、浸润深度和临床分期密切相关(P＜0.01),但与患者年龄、性别无关(P＞0.05).肿瘤患者血清VEGF水平随着KPS评分的降低,而逐渐升高(P＜0.05).结论VEGF作为一个促进血管渗透性和促进血管内皮生长的主要因子,在肿瘤发生、生长和转移过程中起着极其重要的作用,并可作为判断恶性肿瘤患者术后有无复发或转移的良好指标,在临床上具有重要的参考价值.     

胃癌患者血清VEGF、MMP-2的表达及其与浸润和转移的关系

[目的]探讨胃癌患者血清VEGF及MMP-2的表达与胃癌浸润和转移的关系。[方法]应用ELISA法检测69例胃癌患者血清VEGF、MMP-2的表达水平，并分析其与临床病理因素间的关系。[结果]低分化胃癌患者血清VEGF阳性率（64．0％）显著高于高、中分化者（36．8％，P〈0．05）；且VEGF、MMP-2表达与肿瘤的浸润深度、淋巴结转移、远处转移及TNM分期均密切相关（P〈0．05）。胃癌患者血清VEGF的阳性表达与MMP-2的阳性表达呈正相关（rs=0．322，P〈0．01）。[结论]VEGF和MMP-2在胃癌的浸润和转移中起重要作用，血清VEGF、MMP-2的表达水平可作为了解胃癌生物掌行为和判断顸后的指标．     

乳腺癌组织中TGFβ1、VEGF、c-erbB-2的表达及其与浸润转移的关系

目的：探讨转化生长因子β1、血管内皮生长因子及c-erbB-2在乳腺癌组织中的表达及其与浸润转移的关系。方法：采用免疫组化EnVision^TM二步检测65例乳腺癌组织中TGFβ1，VEGF，c-erbB-2的表达情况。结果：TGFβ1，VEGF，c-erbB-2的表达均与乳腺癌淋巴结转移密切相关（P＜0．05或P＜0．01），TGFβ1表达还与癌浸润相关（P＜0．01），VEGF表达与TGFβ1,c-erbB-2表达呈显著正相关（P均＜0．01），结论：TGFβ1、VEGF和c-erbB-2的过度表达预示着乳腺癌具有较强的转移能力；3种蛋白的过度表达可能在乳腺癌的浸润转移过程中起协同作用。     

胃癌病人血清VEGF水平的临床意义

目的血管内皮生长因子(vascularendothelialgrowthfactor,VEGF)是一种重要的促血管形成因子,与肿瘤的多种恶性生物学行为密切相关。本研究旨在通过检测血清VEGF,探讨其与胃癌病理指标间的关系,为临床提供参考。方法用酶联免疫法检测63例胃癌患者血清VEGF水平,将其分为表达阴性和阳性两组,根据不同临床病理指标比较两组间的差异。结果VEGF在胃癌病人血清中的表达与患者的性别、年龄、分化程度无统计学意义(P>0.05),而与肿瘤的浸润深度、淋巴结转移、远处器官转移以及肿瘤的TNM分期密切相关(P<0.05)。结论胃癌病人血清VEGF高表达,在排除创伤和炎症的前提下,可能提示肿瘤的活跃生长以及潜在转移。     

大肠癌组织血管内皮生长因子的表达及其与复发转移的关系

目的：研究血管内皮细胞生长因子（ＶＥＧＦ）在大肠癌中的表达及其与复发转移的关系。方法：采用免疫组化法对正常肠粘膜、良性腺瘤入大肠癌中的ＶＥＧＦ进行了定位观察。结果：大肠癌ＶＥＧＦ的表达比正常粘膜上皮及腺瘤细胞明显提高,并且与癌的复发和转移有关,在有复发转移的大肠癌组,ＶＥＧＦ的表达更加明显,结论：ＶＥＧＦ表达水平反映了肿瘤血管内皮细胞增殖儿血管构建的水平,可作为肿瘤预后的一个指标。     

VEGF在大肠癌患者血清中的表达及其意义

[目的]测定大肠癌患者血清中VEGF的含量,探讨VEGF的表达及其意义。[方法]采用ELISA试剂盒检测89例大肠癌患者血清VEGF的表达。[结果]VEGF在大肠癌患者中的表达明显高于正常对照(P<0.05),而且VEGF的表达与淋巴结转移、侵袭程度、病理类型、复发明显相关(P<0.05),与年龄、性别无关(P>0.05)。[结论]VEGF在大肠癌的发生、发展、侵袭、转移过程中发挥重要作用,可作为判断大肠癌转移和预后的有效指标。     

结直肠癌侵袭转移机制研究进展

结直肠癌侵袭转移的机制与很多方面有关,主要包括结直肠癌侵袭转移的相关基因如k-ras、c-met、nm23、c-SRC、HES-6、P107等,肿瘤免疫,肿瘤血管形成,与细胞外基质(ECM)相互作用的相关分子,及一氧化氮等等。本文就目前国内外在这些方面的研究进展作一综述。     

血清CA199与CEA检测对结直肠癌的诊断价值

目的：研究肿瘤相关糖类抗原199（CA199）与癌胚抗原（CEA）检测对结直肠癌的诊断价值。方法：采用电化学发光方法检测44例结直肠癌患者与19例正常人血清中CA199与CEA的水平并进行统计学分析。结果：结直肠癌患者血清中CA199和CEA水平明显高于正常对照组良性对照组（P〈0．05）;治疗后CA199与CEA含量与治疗前相比显著降低（P〈0．05）。结论：CA199与CEA检测结对结直肠癌临床诊断与疗效评价有一定的意义。     

Relationship between expression of CEA,E-cadherin and liver metastasis in colorectal cancer

OBJECTIVE To investigate the expression of E-cadherin and CEA in serum in colorectal carcinoma and their relationship with liver metastasis.
METHODS CEA level was measured post-operatively by radioimmunoassay of 60 patients with colorectal cancer. Immunohistochemical analysis was used to evaluate the expression of E-cadherin.
RESULTS In liver metastasis group, 24 patients （24/26, 92.3%） were high level of CEA, but only 9 patients in non-liver metastasis group. The difference is significant （P = 0.004）. Expression of E-cadherin significantly correlated with differentiation, but was not associated with T stage or N stage. Liver metastatic rate in negative expression was higher than that in positive expression. And the survival analysis showed that time of liver metastasis was significant different in two groups （P 〈 0.05）.
CONCLUSION The expression of CEA in serum can be used to predict liver mestatasis of colorectal cancer after operation. E-cadherin, associated with tumor differentiation, is also a hopeful indicator for the prediction of liver metastasis in patients with colorectal cancer.     

Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma

In serum, the major part of vascular endothelial growth factor derives from in vitro degranulation of granulocytes and platelets. Therefore, plasma may be preferred for vascular endothelial growth factor measurements. However, which specimen is the best predictor of survival is still debated. The present study analyzed the prognostic value of matched preoperative serum and plasma vascular endothelial growth factor concentrations in patients with colorectal cancer. To establish the reference range among healthy people, vascular endothelial growth factor was analyzed in 50 matched EDTA-plasma and serum samples from healthy blood donors. Preoperatively, in 524 patients with colorectal cancer, matched plasma and serum vascular endothelial growth factor concentrations were analyzed. In the colorectal cancer patients, the median plasma vascular endothelial growth factor concentration (44 pg ml(-1)) was significantly (P=0.01) higher than the median plasma vascular endothelial growth factor concentration (30 pg ml(-1)) in the healthy blood donors. In serum, no significant (P=0.30) difference in the median vascular endothelial growth factor concentration was found between colorectal cancer patients (268 pg ml(-1)) and healthy blood donors (220 pg ml(-1)). The preoperative vascular endothelial growth factor concentrations were dichotomized by the 95th percentile of the healthy blood donors (plasma=112 pg ml(-1), serum=533 pg ml(-1)). In univariate survival analyses, both high plasma vascular endothelial growth factor (>112 pg ml(-1)) and high serum vascular endothelial growth factor (>533 pg ml(-1)) predicted a reduced survival. In multivariate survival analyses, high serum vascular endothelial growth factor (>533 pg ml(-1)) independently predicted a reduced survival (HR=1.65, P=0.015), while high plasma vascular endothelial growth factor (>112 pg ml(-1)) did not (HR=1.27, P=0.23). This study indicates that preoperative serum vascular endothelial growth factor apparently is a better predictor of overall survival than the preoperative plasma vascular endothelial growth factor.     

Predictive value of plasma CEA in patients with colorectal carcinoma

Two years follow-up of 46 patients with colorectal carcinoma resected "for cure" shows that of the nine patients with an elevated (less than 5 ng/ml) CEA plasma titer one to six months after surgery, only one, or 11%, had remained disease free. Of the 38 patients with normal (less than 5 ng/ml) plasma CEA, 27, or 71%, were free of disease two years after surgery. In another 85 patients presenting six months to ten years after resection "for cure" of their colorectal carcinoma, normal CEA levels were found in 73, and only five, or 6.4%, of these presented with disease progression when followed for two years; of the 12 patients that presented with CEA values less than 5 ng/ml, disease progression was evident in eight or 67%; in eight patients with CEA levels of greater than 10 ng/ml, the proportion of patients with disease progression increased to 87.5% (7/8). When a patient with a history of colorectal cancer, but seemingly free of disease, presents with levels not only repeatedly above normal (greater than 5 ng/ml) but above the levels found in some nonmalignant conditions (greater than 10 ng/ml), thorough re-examination of the patient to locate the site of possible disease progression is indicated. In 14 such patients further diagnostic methods showed local recurrences in four, metastasis limited to the liver in six, and other metastasis in four. In conclusion, in patients with colorectal carcinoma postoperative elevated CEA plasma levels are a sign of poor prognosis. Consistently elevated CEA levels (greater than 10 ng/ml) are a strong indication of disease progression.     

结直肠癌患者血清VEGF水平变化的临床意义

目的 :探讨结直肠癌患者血清血管内皮生长因子 (vascularendothelialgrowthfactor ,VEGF)水平变化的临床意义。方法 :采用双抗夹心ELISA法检测 45例结直肠癌患者血清VEGF水平 ,并与正常人比较。结果 :结直肠癌患者血清VEGF水平 [( 199 47± 15 6 69)pg/mL]显著高于正常对照组 [( 5 1 2 3± 2 2 66)pg/mL] ,P =0 0 0 0 ;有血管侵犯 [( 2 5 1 63±170 19)pg/mL ]、淋巴结转移 [( 2 66 3 9±162 49)pg/mL]和肝脏转移 [( 3 14 48± 2 19 89)pg/mL]的结直肠癌患者血清VEGF水平明显高于无血管侵犯 [( 12 1 2 3± 91 91)pg/mL]、无淋巴结转移 [( 189 2 6± 47 14 )pg/mL]和无肝脏转移 [( 15 7 65± 10 1 86)pg/mL]的患者 ,分别P =0 0 0 5 ,P =0 0 0 0 ,P =0 0 0 2 ;Duke’sC、D期的结直肠癌患者血清VEGF水平 [( 2 60 74±174 72 )pg/mL]显著高于Duke’sA、B期患者[( 115 63± 69 10 )pg/mL] ,P =0 0 0 1;结直肠肿瘤≥ 5cm的患者血清VEGF水平 [( 2 44 74±171 18)pg/mL]明显高于肿瘤 <5cm的患者[( 12 4 92± 92 62 )pg/mL] ,P =0 0 0 4。血清VEGF水平与患者性别、年龄和组织病理学类型无明显关系。结论 :血清VEGF有可能成为一个新的肿瘤标志物而用于结直肠癌诊断、病情进展的动态监测及预后判断的     

Serum polyamine alterations in surgical patients with colorectal carcinoma

Polyamines, by virture of their regulatory role in the cellular synthesis of DNA, RNA, and protein, are potential indicators of malignant growth. In view of this, serum polyamine levels of patients with colorectal carcinoma or benign bowel disease were examined. Of 53 patients with colorectal carcinoma, 35 (66%) showed elevations of 1 or more polyamines. Nine patients with benign bowel disease (villous adenoma, Gardner's syndrome, familial polyposis, and diverticulitis) showed normal serum polyamine levels except 1 patient with a villous adenoma. Patients with colorectal carcinoma were designated stage A, B, C, or D depending on the progression of their disease. All patients classified as D showed elevation of 1 or more polyamines. Serum polyamines became elevated following surgery in patients with colorectal carcinoma as well as those with benign bowel diseases, suggesting a relationship to the surgical procedure. Preliminary longitudinal studies of patients with colorectal carcinoma (B stage) undergoing curable surgical procedures show normal polyamine levels and no evidence of disease at 15 months.